Compliance with GMP and Other Relevant Regulations and Collection and Reporting of Adverse Event Information
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
3 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Compliance with GMP and other applicable laws and regulations; conducting research, development and production in compliance with laws and regulations; providing education on pharmaceutical-related information and applicable laws and regulations; and promptly collecting and reporting adverse-event information」
The company has reconfirmed its initiatives addressing material issues, including compliance with GMP and other applicable laws and regulations, education, and the prompt collection and reporting of adverse-event information. - FY2024First statedAnnual report
「Compliance with GMP and other applicable laws and regulations; conducting research, development and production in compliance with laws and regulations; providing education on pharmaceutical-related information and applicable laws and regulations; and promptly collecting and reporting adverse-event information」
The company has for the first time organized its policy of continuously addressing material issues, including research, development and production in compliance with GMP and other applicable laws and regulations, education, and the prompt collection and reporting of adverse-event information.